caa a22 4500 44529910X CHVBK 20180317142551.0 cr unu---uuuuu 170323e20100701xx s 000 0 eng 10.1007/s11940-010-0077-6 doi (NATIONALLICENCE)springer-10.1007/s11940-010-0077-6 Newly Diagnosed High-Grade Gliomas [Elektronische Daten] [Pierre Giglio, John Lee Villano] Opinion statement: High-grade or malignant gliomas are aggressive cancers. The World Health Organization (WHO) grading system recognizes grade III and grade IV primary brain tumors of astrocytic, oligodendroglial, or mixed lineage. Identification of these tumors is prompted by symptoms such as insidious headaches, seizures, or focal weakness or numbness, with imaging findings of an enhancing mass lesion. Following surgery, radiation therapy has been known since the late 1970s to improve survival in malignant gliomas. More recently, the concurrent use of temozolomide (TMZ) and radiation therapy and the incorporation of bevacizumab have offered hope for patients with glioblastoma (WHO grade IV glioma). Although radiation is regularly used for up-front treatment of grade III gliomas, the role of chemotherapy is still being refined. In the past, patients with high-grade gliomas were often referred to a dedicated neuro-oncology center, but with improved outcomes and increased survival, these patients now are often treated by community oncologists. We believe substantial changes will develop with pending investigations that refine the dose and length of TMZ treatment, define specialized treatment for the elderly, and assess efficacy of bevacizumab in up-front therapy. The field is also conducting the required studies to define the role of chemotherapy for grade III malignant gliomas. These promising advances are needed as most patients with high-grade gliomas still succumb to their disease. Springer Science+Business Media, LLC, 2010 Giglio Pierre Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street CSB 306B, 29425, Charleston, SC, USA aut Villano John Lee Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 909 S. Wolcott Avenue, Room 3133 (M/C 734), 60612, Chicago, IL, USA aut Current Treatment Options in Neurology Current Science Inc. 12/4(2010-07-01), 309-320 1092-8480 12:4<309 2010 12 11940 https://doi.org/10.1007/s11940-010-0077-6 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11940-010-0077-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Giglio Pierre Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street CSB 306B, 29425, Charleston, SC, USA aut NATIONALLICENCE 700 1- Villano John Lee Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 909 S. Wolcott Avenue, Room 3133 (M/C 734), 60612, Chicago, IL, USA aut NATIONALLICENCE 773 0- Current Treatment Options in Neurology Current Science Inc 12/4(2010-07-01), 309-320 1092-8480 12:4<309 2010 12 11940 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer